Furthermore,this new chemistry also promises to unlock access to new derivativesto target other Y220 mutants, including Y220S and Y220N, which togetheraccount for another 10,000–20,000 new cancer cases per yearworldwide.22 Overall, this study validatestwo new chemical probes for the prominent p53 cancer mutant Y220Cwith nanomolar in vitro binding affinity and opensexciting opportunities for chemically addressing a range of p53-Y220Xmutants for which high-affinity ligands currently do not exist. This evidence concerns the gene TP53 and cancer.